Cargando…

Sex Dimorphism of Nonalcoholic Fatty Liver Disease (NAFLD) in Pparg-Null Mice

Men with nonalcoholic fatty liver disease (NAFLD) are more exposed to nonalcoholic steatohepatitis (NASH) and liver fibrosis than women. However, the underlying molecular mechanisms of NALFD sex dimorphism are unclear. We combined gene expression, histological and lipidomic analyses to systematicall...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schiffrin, Mariano, Winkler, Carine, Quignodon, Laure, Naldi, Aurélien, Trötzmüller, Martin, Köfeler, Harald, Henry, Hugues, Parini, Paolo, Desvergne, Béatrice, Gilardi, Federica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467431/ https://www.ncbi.nlm.nih.gov/pubmed/34576136 http://dx.doi.org/10.3390/ijms22189969

Ejemplares similares

Nephropathy in Pparg-null mice highlights PPARγ systemic activities in metabolism and in the immune system
por: Toffoli, Barbara, et al.
Publicado: (2017)

Peroxisome Proliferator-Activated Receptor β/δ in the Brain: Facts and Hypothesis
por: Hall, M. G., et al.
Publicado: (2008)

Lack of Adipocytes Alters Hematopoiesis in Lipodystrophic Mice
por: Wilson, Anne, et al.
Publicado: (2018)

Renal mineralocorticoid receptor expression is reduced in lipoatrophy
por: Toffoli, Barbara, et al.
Publicado: (2019)

Genome-Wide Analysis of SREBP1 Activity around the Clock Reveals Its Combined Dependency on Nutrient and Circadian Signals
por: Gilardi, Federica, et al.
Publicado: (2014)

Lack of Adiponectin Drives Hyperosteoclastogenesis in Lipoatrophic Mice
por: Madel, Maria-Bernadette, et al.
Publicado: (2021)

Lipidomics from sample preparation to data analysis: a primer
por: Züllig, Thomas, et al.
Publicado: (2019)

The Genetics of PPARG and the Skeleton
por: Ackert-Bicknell, Cheryl, et al.
Publicado: (2006)

NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk
por: Ballestri, Stefano, et al.
Publicado: (2017)

System analysis of cross-talk between nuclear receptors reveals an opposite regulation of the cell cycle by LXR and FXR in human HepaRG liver cells
por: Wigger, Leonore, et al.
Publicado: (2019)

PPARγ Controls Ectopic Adipogenesis and Cross-Talks with Myogenesis During Skeletal Muscle Regeneration
por: Dammone, Gabriele, et al.
Publicado: (2018)

Anti-adipogenic signals at the onset of obesity-related inflammation in white adipose tissue
por: Caputo, Tiziana, et al.
Publicado: (2020)

Mass Spectrometry Based Lipidomics: An Overview of Technological Platforms
por: Köfeler, Harald C., et al.
Publicado: (2012)

Quantitative analysis of N‐acylphosphatidylethanolamine molecular species in rat brain using solid‐phase extraction combined with reversed‐phase chromatography and tandem mass spectrometry
por: Triebl, Alexander, et al.
Publicado: (2016)

The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD)
por: Carulli, Lucia, et al.
Publicado: (2019)

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

Mice with null mutation of Ceacam1 develop nonalcoholic steatohepatitis
por: Ghosh, Sumona, et al.
Publicado: (2010)

Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD)
por: Del Campo, José A, et al.
Publicado: (2018)

Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD)
por: Zarghamravanbakhsh, Paria, et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis
por: Dorairaj, Vicneswarry, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease shows significant sex dimorphism
por: Chen, Xing-Yu, et al.
Publicado: (2022)

PPARG as therapeutic target for antifibrotic therapy
por: Ghallab, Ahmed, et al.
Publicado: (2020)

Assessment of lipidomic species in hepatocyte lipid droplets from stressed mouse models
por: Hartler, Jürgen, et al.
Publicado: (2014)

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
por: Younossi, Zobair M., et al.
Publicado: (2023)

Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research
por: Lonardo, Amedeo, et al.
Publicado: (2020)

PPARG Pro12Ala Polymorphism with CKD in Asians: A Meta-Analysis Combined with a Case-Control Study—A Key for Reaching Null Association
por: Chen, Hsiang-Cheng, et al.
Publicado: (2020)

Nutritional Management of Insulin Resistance in Nonalcoholic Fatty Liver Disease (NAFLD)
por: Conlon, Beth A., et al.
Publicado: (2013)

Nonalcoholic Fatty Liver Disease (NAFLD) Name Change: Requiem or Reveille?
por: Singh, Shivaram P., et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
por: Di Ciaula, Agostino, et al.
Publicado: (2021)

Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies
por: Fang, Tingyu, et al.
Publicado: (2022)

Clustering NAFLD: phenotypes of nonalcoholic fatty liver disease and their differing trajectories
por: Kantartzis, Konstantinos, et al.
Publicado: (2023)

Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma
por: Enooku, Kenichiro, et al.
Publicado: (2019)

Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH)
por: Vandel, Jimmy, et al.
Publicado: (2020)

PPARG Binding Landscapes in Macrophages Suggest a Genome-Wide Contribution of PU.1 to Divergent PPARG Binding in Human and Mouse
por: Pott, Sebastian, et al.
Publicado: (2012)

A Metabolomics Workflow for Analyzing Complex Biological Samples Using a Combined Method of Untargeted and Target-List Based Approaches
por: Züllig, Thomas, et al.
Publicado: (2020)

Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0
por: Vairetti, Mariapia, et al.
Publicado: (2022)

Sugar-Sweetened Beverages and Artificially Sweetened Beverages Consumption and the Risk of Nonalcoholic Fatty Liver (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Tseng, Tung-Sung, et al.
Publicado: (2023)

Formulation for Effective Screening and Management of Nonalcoholic Steatohepatitis: Noninvasive NAFLD Management Strategy
por: Hirose, Kanae, et al.
Publicado: (2016)

Effects of Natural Products on Fructose-Induced Nonalcoholic Fatty Liver Disease (NAFLD)
por: Chen, Qian, et al.
Publicado: (2017)

Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
por: Pafili, Kalliopi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tfnirqpkob44tkov1u81q7ocrs